ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib is a 2-phenylaminopyrimidine derivative neoplastic agent that has been approved by the FDA for the treatment of CML by inhibiting BCR–ABL tyrosine kinase [36].